Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Damian Marron Ph.D. | Interim CEO & Director | 350k | -- | 1962 |
| Mr. Thoas Fioretos M.D., Ph.D. | Founder & Scientific Advisor | 355k | -- | 1962 |
| Mr. Marcus Järås | Founder & Scientific Advisor | -- | -- | -- |
| Mr. Kjell Sjöström | Founder | -- | -- | -- |
| Mr. Patrik Renblad | Chief Financial Officer | -- | -- | 1970 |
| Dr. David Liberg | Chief Scientific Officer | -- | -- | 1969 |
| Nina Valkama | Executive Assistant of Administration & Finance | -- | -- | -- |
| Johanna Christensen | Financial Controller | -- | -- | -- |
Cantargia AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 22
Description
Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Corporate Governance
Upcoming Events
May 13, 2025 at 5:00 AM UTC
Cantargia AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available